X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Luminate® (risuteganib) is a novel anti-integrin peptide that targets the multiple integrin heterodimers involved in the pathophysiology of dry AMD, it is being investigated for the treatment of intermediate, non-exudative age-related macular degeneration.
Lead Product(s): Risuteganib
Therapeutic Area: Ophthalmology Product Name: Luminate
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
Pre-clinical data suggest that Luminate (risuteganib), Allegro’s lead investigational compound in retina, may simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases, such as dry AMD.
Lead Product(s): Risuteganib
Therapeutic Area: Ophthalmology Product Name: Luminate
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.
Lead Product(s): Risuteganib
Therapeutic Area: Ophthalmology Product Name: Luminate
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
The agreement provides Bausch with global rights for risuteganib, Allegro's lead investigational compound in retina, including Other ophthalmology assets such as Allegro's ALG-1007, a topical integrin regulator under investigation for the treatment of dry eye disease.
Lead Product(s): Risuteganib
Therapeutic Area: Ophthalmology Product Name: Luminate
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: $50.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition September 21, 2020
Details:
Bausch Health, has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro, including global rights for risuteganib (Luminate). Allegro include ALG-1007, a topical integrin regulator under investigation for treatment of dry eye disease.
Lead Product(s): Risuteganib
Therapeutic Area: Ophthalmology Product Name: Luminate
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
